Key PointsRegeneron’s revenue is growing at a good clip despite declining Eylea sales.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.
Veytics Intelligence
Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share
